-
Article
Comparison of out-of-pocket costs and adherence between the two arms of the prospective, randomized abiraterone food effect trial
Abiraterone acetate, prescribed for metastatic prostate cancer, has enhanced absorption with food. This effect was exploited in a randomized trial which showed noninferiority of PSA decline for 250 mg abirater...
-
Article
Open AccessSteroid-refractory dermatologic and pulmonary toxicity in a patient on rituximab treated with pembrolizumab for progressive urothelial carcinoma: a case report
Increasingly widespread use of programmed cell death protein 1 (PD-1) immune checkpoint inhibitors (ICIs) for treatment of a variety of progressive malignancies continues to reveal a range of immune-related ad...
-
Chapter
Adjuvant Chemotherapy in Bladder Cancer
There is a high rate of recurrence in patients who undergo just radical cystectomy for muscle-invasive bladder cancer. Adjuvant chemotherapy is recommended for patients with pT3/T4 and/or pN+ M0 muscle-invasiv...
-
Article
Patient-provider communications about pharmacogenomic results increase patient recall of medication changes
Effective doctor–patient communication is critical for disease management, especially when considering genetic information. We studied patient-provider communications after implementing a point-of-care pharmac...
-
Article
Open AccessEPHB4 inhibition activates ER stress to promote immunogenic cell death of prostate cancer cells
The EPHB4 receptor is implicated in the development of several epithelial tumors and is a promising therapeutic target, including in prostate tumors in which EPHB4 is overexpressed and promotes tumorigenicity....
-
Article
Open AccessComplete response of renal cell carcinoma vena cava tumor thrombus to neoadjuvant immunotherapy
Clinically localized renal cell carcinoma is treated primarily with surgery followed by observation or adjuvant sunitinib in selected high-risk patients. The checkpoint inhibitor immunotherapeutic agents nivol...
-
Article
Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
In the version of this article originally published, there was an error in Fig. 2n. The top line of the HR comparison chart originally was Atezo + bev vs sun. It should have been Atezo + bev vs atezo. The erro...
-
Article
Open AccessPhase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC)
Background Tivantinib is a non-ATP competitive inhibitor of c-MET receptor tyrosine kinase that may have additional cytotoxic mechanisms including tubulin inhibition. Prostate cancer demonstrates higher c-MET exp...
-
Article
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
We describe results from IMmotion150, a randomized phase 2 study of atezolizumab (anti-PD-L1) alone or combined with bevacizumab (anti-VEGF) versus sunitinib in 305 patients with treatment-naive metastatic ren...
-
Article
Effect of Renal Impairment on the Pharmacokinetics and Safety of Axitinib
Axitinib, an inhibitor of vascular endothelial growth factor (VEGF) receptors, is approved as second-line treatment for advanced renal cell carcinoma (RCC). Agents targeting the VEGF pathway may induce renal t...
-
Article
Open AccessMarkers of inflammation are associated with clinical outcomes in patients with metastatic renal cell carcinoma treated with nivolumab
-
Article
Erratum to: The Combination of Insulin-Like Growth Factor Receptor 1 (IGF1R) Antibody Cixutumumab and Mitotane as a First-Line Therapy for Patients with Recurrent/Metastatic Adrenocortical Carcinoma: a Multi-institutional NCI-Sponsored Trial
-
Article
Open AccessQuantitative characterization of androgen receptor protein expression and cellular localization in circulating tumor cells from patients with metastatic castration-resistant prostate cancer
Many current therapies for metastatic castration-resistant prostate cancer (mCRPC) are aimed at AR signaling; however, resistance to these therapies is inevitable. To personalize CRPC therapy in an individual ...
-
Article
The Combination of Insulin-Like Growth Factor Receptor 1 (IGF1R) Antibody Cixutumumab and Mitotane as a First-Line Therapy for Patients with Recurrent/Metastatic Adrenocortical Carcinoma: a Multi-institutional NCI-Sponsored Trial
Adrenocortical carcinoma (ACC) is an aggressive malignancy, which lacks an effective systemic treatment. Abnormal activation of insulin-like growth factor receptor 1 (IGF1R) has been frequently observed. Precl...
-
Article
Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium
Background Treatment options for metastatic colorectal cancer (CRC) are limited after a fluoropyrimidine, oxaliplatin and irinotecan; novel agents need to be explored in this setting. Dasatinib, ...
-
Article
A phase I study of continuous infusion cilengitide in patients with solid tumors
Background: Cilengitide (EMD121974) is a cyclized pentapeptide that is a potent and selective integrin antagonist which has shown activity in malignant gliomas. In all previous studies, cilengiti...
-
Article
Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium
Background Sorafenib, an inhibitor of B-raf, VEGFR2, and PDGFR-β, has activity against pancreatic cancer in preclinical models. In a phase I trial of gemcitabine plus sorafenib, 57% of pa...
-
Chapter
Variant Renal Cell Carcinoma Histologies: Therapeutic Considerations
Non-clear cell renal cell carcinoma (NCCRCC) accounts for approximately 20–25% of all cases of renal epithelial cancers, and a significant proportion of those patients present with advanced disease. Once a pat...
-
Article
Baseline patient-reported kidney cancer-specific symptoms as an indicator for median survival in sorafenib-refractory metastatic renal cell carcinoma
The goal of the study was to determine the relationship of baseline Functional Assessment of Cancer Therapy–Kidney Cancer Symptom Index (FKSI) scores with median progression-free survival (mPFS) and median ove...
-
Article
Renal medullary-like carcinoma in an adult without sickle cell hemoglobinopathy
Renal medullary carcinoma has been almost exclusively diagnosed in patients with sickle cell anemia. O'Donnell et al. present a case of this rare and aggressive cancer in an adult with no detectable hemoglobinopa...
